Calidi Biotherapeutics, Inc. entered into a settlement agreement with an investor, purchasing a $2.0 million convertible promissory note and issuing a $1.5 million convertible note in settlement of a claim. Amendments were made to the notes regarding conversion price, mandatory conversion, and demand registration rights.